<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877379</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-7145-102</org_study_id>
    <secondary_id>272201600029C-P00007-9999-2</secondary_id>
    <nct_id>NCT04877379</nct_id>
  </id_info>
  <brief_title>VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers</brief_title>
  <official_title>VNRX-7145-102: A Randomized, Drug-Drug Interaction Study to Assess the Safety and Pharmacokinetics (PK) of VNRX-7145 and VNRX-5024 (Ceftibuten) in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venatorx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Venatorx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide an initial assessment of the safety and PK of VNRX-7145 and VNRX-5024&#xD;
      (ceftibuten) when administered as single agents and with co-administration in a single dose&#xD;
      cross-over design in Part 1. In Part 2, subjects will receive 500 mg of VNRX-7145 or matching&#xD;
      placebo q8h for 10 days. VNRX-7145 and VNRX-5024 (ceftibuten) will be administered every 8&#xD;
      hours (q8h) for 10 days at 2 dose levels of VNRX-7145 in Part 3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1: Crossover Parts 2&amp;3: Parallel</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part 1: Unblinded Parts 2&amp;3: Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Cmax</measure>
    <time_frame>0-48 hours</time_frame>
    <description>concentration time data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: AUC0-inf</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Area under the concentration-time curve from time-zero extrapolated to infinity based on collected PK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 2&amp;3: Number of subjects with adverse events</measure>
    <time_frame>Day 15 (+2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with adverse events</measure>
    <time_frame>Day 14 (+2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2&amp;3: AUC0-tau</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2&amp;3: AUC0-tau</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2&amp;3: Cmax</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 2&amp;3: Cmax</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single doses of VNRX-7145 or VNRX-5024 alone and in combination. All subjects will receive study drug in the sequence specified by the randomization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration of VNRX-7145 q8h for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose administration of placebo q8h for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration of low dose VNRX-7145 + VNRX-5024</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration of high dose VNRX-7145 + VNRX-5024</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose administration of Placebo (matching VNRX-7145 + VNRX-5024)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-7145</intervention_name>
    <description>β-lactamase inhibitor</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2A</arm_group_label>
    <arm_group_label>Part 3A</arm_group_label>
    <arm_group_label>Part 3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-5024 (ceftibuten)</intervention_name>
    <description>β-lactam antibiotic</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 3A</arm_group_label>
    <arm_group_label>Part 3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part 2B</arm_group_label>
    <arm_group_label>Part 3C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults 18-55 years&#xD;
&#xD;
          2. Males or non-pregnant, non-lactating females&#xD;
&#xD;
          3. Body mass index (BMI): ≥18.5 kg/m2 and ≤32.0 kg/m2&#xD;
&#xD;
          4. Normal blood pressure&#xD;
&#xD;
          5. Normal lab tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, autoimmune, hematologic, neoplastic, or neurological&#xD;
             disorders&#xD;
&#xD;
          2. History of drug allergy or hypersensitivity to penicillin, cephalosporin, or&#xD;
             beta-lactam antibacterial drug&#xD;
&#xD;
          3. Use of antacid medications&#xD;
&#xD;
          4. Abnormal ECG or history of clinically significant abnormal rhythm disorder&#xD;
&#xD;
          5. Positive alcohol, drug, or tobacco use/test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Venatorx Clinical</last_name>
    <phone>610-644-8935</phone>
    <email>venatorxclinical@venatorx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences - Early Development Services</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftibuten</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

